Nanosolvated microtubule-modulating chemotherapeutics: A case-to-case study

Anti-Cancer Drugs

Volumn 24, Issue 4, 2013, Pages 327-336

  Jain, Vibhor ^a   Jain, Bindu ^a   Tiwari, Prashant ^a   Saini, Jyoti ^c   Jain, Upendra K ^c   Pandey, Ravi S ^b   Kumar, Manoj ^b   Katare, Om P ^d   Chandra, Ramesh ^e   Madan, Jitender ^c  

^a Chouksey College of Engineering   (India)

^b GURU GHASIDAS UNIVERSITY   (India)

^c Chandigarh College of Pharmacy   (India)

^d PANJAB UNIVERSITY   (India)

^e UNIVERSITY OF DELHI   (India)

Author keywords

bioavailability; microtubule modulating drugs; nanosolvation; oral delivery; pharmacokinetic; solubility

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; COLCHICINE; COMBRETASTATIN; CREMOPHOR; CYCLODEXTRIN DERIVATIVE; DIETHYLENE GLYCOL MONOETHYL ETHER; DISCODERMOLIDE; DOCETAXEL; ELEUTHEROBIN; EPOTHILONE DERIVATIVE; EUGENOL; LABRASOL; LAULIMALIDE; LIPOSOME; MICROTUBULE MODULATING AGENT; MULTIDRUG RESISTANCE PROTEIN; MYRISTIC ACID ISOPROPYL ESTER; NANOPARTICLE; NOSCAPINE; NOSCAPINOID DERIVATIVE; PACLITAXEL; SAQUINAVIR; SARCODICTYIN DERIVATIVE; TAXANE DERIVATIVE; TOCOFERSOLAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CHEMICAL PROCEDURES; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DISPERSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG SOLUBILITY; DRUG SYNTHESIS; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; KAPOSI SARCOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MICELLE; NANOEMULSION; NANOSOLVATION; NAUSEA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; PH; PKA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID DISPERSION; SOLVATION; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; COLCHICINE; CYCLODEXTRINS; DRUG DELIVERY SYSTEMS; EMULSIONS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INTESTINAL ABSORPTION; LIPOSOMES; MICELLES; MICROTUBULES; NANOTECHNOLOGY; NOSCAPINE; PARTICLE SIZE; POLYMERIZATION; SOLUBILITY; TAXOIDS; TUBULIN; TUBULIN MODULATORS; VINCA ALKALOIDS; WATER;

EID: 84875056393     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835ec414     Document Type: Review

References (85)

1. Shargel L, Yu AB. Applied biopharmaceutics and pharmacokinetics. 4th ed. New York:McGraw-Hill; 1999
2. La Porte CJL, Back DJ, Blaschke T. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3:4-14
3. Lledo-Garcia R, Nacher A, Casabo VG, Merino-Sanjuan M. A pharmacokinetic model for evaluating the impact of hepatic and intestinal firstpass loss of saquinavir in the rat. Drug Metab Dispos 2011; 39:294-301
4. Lennemas H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data:Experience from in vivo dissolution and permeability studies in humans. Curr Drug Metab 2007; 8:645-657
5. Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, Yamashita S. Site of absorption after oral administration: Assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci 2006; 29:240-250
6. Ghilzai MK. Advances in the delivery of large size drug molecules. Innov Pharm Technol 2004;102-108
7. Leonard TW, Lynch J, McKenna MJ, Brayden DJ. Promoting absorption of drugs in human medium chain fatty acid-based solid dosage forms: GIPET. Expert Opin Drug Deliv 2006; 3:685-692
8. Majundar S, Mitra A. Chemical modification and formulation approaches to elevated drug transport across cell membranes. Expert Opin Drug Deliv 2006; 3:511-527
9. Vemulapalli V, Khan NM, Jasti BR. Physicochemical characteristics that influence the transport of drugs across intestinal barrier. AAPS News Mag 2007;18-21
10. Hellriegel ET, Bjornsson TD, Hauck WW. Inter-patient variability in bioavailability is related to the extent of absorption:Implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996; 60:601-607
11. Aungst BJ. Intestinal permeation enhancers. J Pharm Sci 2000; 89: 429-442
12. Olsson B, Bolme P, Dahlstrom B, Marcus C. Excretion of noscapine in human breast milk. Eur J Clin Pharmacol 1986; 30:213-215
13. Beg S, Swain S, Rizwan M, Irfanuddin M, Malini DS. Bioavailability enhancement strategies: Basics, formulation approaches and regulatory considerations. Curr Drug Deliv 2011; 8:691-702
14. Stella VJ, Rajewski RA. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res 1997; 14:556-567
15. Madan J, Dhiman N, Parmar VK, Sardana S, Bharatam PV, Aneja R, et al. Inclusion complexes of noscapine in b-cyclodextrin offer better solubility and improved pharmacokinetics. Cancer Chemother Pharmacol 2010; 65:537-548
16. Madan J, Dhiman N, Sardana S, Aneja R, Chandra R, Katyal A. Long circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine:Preparation, in-vitro characterization, structure elucidation, pharmacokinetic and cytotoxicity analysis. Anticancer Drugs 2011; 22:543-555
17. Chauhan R, Madan J, Kaushik D, Sardana S, Sharma R. Inclusion complex of colchicine in hydroxypropyl-b-cyclodextrin tenders better solubility and improved pharmacokinetics. Pharm Dev Technol 2011; 18:313-322
18. Alvi IA, Madan J, Kaushik D, Sardana S, Pandey RS, Ali A. Comparative study of transfersomes, liposomes and niosomes for topical delivery of 5-fluorouracil to skin cancer cells:Preparation, characterization, in-vitro release and cytotoxicity analysis. Anticancer Drugs 2011; 22:774-782
19. Garg M, Madan J, Pandey RS, Sardana S, Katyal A, Chandra R. Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells. Anticancer Drugs 2012; 23:836-845
20. Madan J, Baruah B, Nagaraju M, Abdalla MO, Yates C, Turner T, et al. Molecular cycloencapsulation augments solubility and improves therapeutic index of brominated noscapine in prostate cancer cells. Mol Pharm 2012; 9:1470-1480
21. Chandra R, Madan J, Singh P, Chandra A, Kumar P, Tomar V, et al. Implications of nanoscale based drug delivery systems in delivery and targeting tubulin binding agent, noscapine in cancer cells. Curr Drug Metab 2012; 13:1476-1483
22. Jordan MA,Wilson L. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10:123-130
23. Giannakakou P, Sackett D, Fojo T. Tubulin/microtubules: Still a promising target for new chemotherapeutic agents. J Natl Cancer Inst 2000; 92: 182-183
24. Ligon LA, Shelly SS, Tokito M, Holzbaur EL. The microtubule plus-end proteins EB1 and dynactin have differential effects on microtubule polymerization. Mol Biol Cell 2003; 14:1405-1417
25. Galmarini CM, Kamath K, Vanier-Viornery A, Hervieu V, Peiller E, Falette N, et al. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 2003; 88:1793-1799
26. Waterman-Storer C, Salmon ED. Microtubule dynamics: Tread milling comes around again. Curr Biol 1997; 7:369-372
27. Mitchison TJ, Kirschner M. Dynamic instability of microtubule growth. Nature 1984; 312:237-242
28. Johnson IS, Wright HF, Svoboda GH. Experimental basis for clinical evaluation of anti-Tumor principles derived from Vinca rosea Linn. J Lab Clin Med 1959; 54:830-837
29. Noble RL, Beer CT, Cutts JH. Further biological activities of vinca leukoblastine: An alkaloid isolated from Vinca rosea (L.). Biochem Pharmacol 1958; 1:347-348
30. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol 1999; 29:267-287
31. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249:9-17
32. Sahenk Z, Barohn R, New P, Mendell Jr. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 1994; 51:726-729
33. Jordan MA, Thrower D,Wilson L. Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 1991; 51:2212-2222
34. Bai RB, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 1990; 265:17141-17149
35. Na GC, Timasheff SN. Thermodynamic linkage between tubulin selfassociation and the binding of vinblastine. Biochemistry 1980; 19: 1347-1354
36. Na GC, Timasheff SN. Stoichiometry of the vinblastine-induced selfassociation of calf brain tubulin. Biochem Soc Trans 1980; 8:1347-1354
37. Jordan MA, Margolis RL, Himes RH, Wilson L. Identification of a distinct class of vinblastine binding sites on microtubules. J Mol Biol 1986; 187: 61-73
38. Singer WD, Jordan MA, Wilson L, Himes RH. Binding of vinblastine to stabilized microtubules. Mol Pharmacol 1989; 36:366-370
39. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57:229-233
40. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, et al. Paclitaxel resistance in non-small cell lung cancer associated with beta-Tubulin gene mutations. J Clin Oncol 1999; 17:1786-1793
41. Banerjee A. Increased levels of tyrosinated alpha-, beta (III)-, and beta (IV)-Tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun 2002; 293:598-601
42. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III beta-Tubulin sensitize drug-resistant cells to taxol. Br J Cancer 1999; 80:1020-1025
43. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-Tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003; 9:2992-2997
44. Gumerlock P, Mack P, Gustafsson M, Togonon M, Gandara D. p27 induction as a potential p53-independent mechanism of apoptotic response to docetaxel in non-small cell lung (NSCL) and prostate carcinomas (CaP). Clin Cancer Res 1999; 5:s3859
45. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-2327
46. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277:665-667
47. Horwitz SB. How to make taxol from scratch. Nature 1994; 367:593-594
48. Von Hoff DD. The taxoids: Same roots, different drugs. Semin Oncol 1997; 24:S13-3-S13-10
49. Markman M. Managing taxane toxicities. Support Care Cancer 2003; 11:144-147
50. Nogales E,Wolf SG, Khan IA, Luduena RF, Downing KA. Structure of tubulin at 6.5 A °and location of the taxol-binding site. Nature 1995; 375:424-427
51. Nogales E. Structural insights into microtubule function. Annu Rev Biophys Biomol Struct 2001; 30:397-420
52. Pryor DE, O'Brate A, Bilcer G, Di'az JF, Wang Y, Wang Y, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002; 41:9109-9115
53. Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther 1991; 512:377-401
54. Skoufias D,Wilson L. Mechanism of inhibition of microtubule polymerization by colchicine:Inhibitory potencies of unliganded colchicine and tubulin- colchicine complexes. Biochemistry 1992; 31:738-746
55. Aggarwal S, Ghosh NN, Aneja R, Joshi H, Chandra R. Mass spectral studies on aryl-substituted N-carbamoyl/N-Thiocarbamoyl narcotine and related compounds. Rapid Commun Mass Spectrom 2002; 16:923-928
56. Zhou J, Gupta K, Aggarwal S, Aneja R, Chandra R, Panda D, et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 2003; 63:799-807
57. Zhou J, Liu M, Aneja R, Chandra R, Joshi HC. Enhancement of paclitaxelinduced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-Targeting agent EM012. Biochem Pharmacol 2004; 68: 2435-2441
58. Naik PK, Chatterji BP, Vangapandu SN, Aneja R, Chandra R, Kanteveri S, et al. Rational design, synthesis and biological evaluations of aminonoscapine: A high affinity tubulin-binding noscapinoid. J Comput Aided Mol Des 2011; 25:443-454
59. Mishra RC, Karna P, Gundala SR, Pannu V, Stanton RA, Gupta KK, et al. Second generation benzofuranone ring substituted noscapine analogs: Synthesis and biological evaluation. Biochem Pharmacol 2011; 82: 110-121
60. Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: A new molecular perspective. Med Res Rev 2011; 31: 443-481
61. Skwarczynski M, Hayashi Y, Kiso Y. Paclitaxel prodrugs: Toward smarter delivery of anticancer agents. J Med Chem 2006; 14:7253-7269
62. Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ, et al. Docetaxel microemulsion for enhanced oral bioavailability:Preparation and in vitro and in vivo evaluation. J Control Release 2009; 3:86-94
63. Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS:Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005; 25:445-453
64. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, NooijenWJ, Schellens JHM, van Tellingen O. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 2000; 6:4416-4421
65. Shen Q,Wang Y, Zhang Y. Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. Int J Nanomedicine 2011; 6:1237-1243
66. Khandavilli S, Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery:Peroral and dermal delivery studies in rats. J Invest Dermatol 2007; 127:154-162
67. Yang T, Cui FD, Choi MK, Lin H, Chung SJ, Shim CK, et al. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv 2007; 14:301-308
68. Hamada H, Ishihara K, Masuoka N, Mikuni K, Nakajima N. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J BioSci Bioeng 2006; 102:369-371
69. Liu Y, Chen GS, Chen Y, Cao DX, Ge ZQ, Yuan YJ. Inclusion complexes of paclitaxel and oligo(ethylenediamino) bridged bis(beta-cyclodextrin)s: Solubilization and antitumor activity. Bioorg Med Chem 2004; 12: 5767-5775
70. Mo R, Jin X, Li N, Ju C, Sun M, Zhang C, et al. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials 2011; 32:4609-4620
71. Roger E, Lagarce F, Garcion E, Benoit JP. Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur J Pharm Sci 2010; 40:422-429
72. De Jaeghere F, Allemann E, Cerny R, Galli B, Steulet AF, Muller I, et al. pH-dependent dissolving nano- And microparticles for improved peroral delivery of a highly lipophilic compound in dogs. AAPS PharmSci 2001; 3:8
73. Park KH, Chhowalla M, Iqbal Z, Sesti F. Single-walled carbon nanotubes are a new class of ion channel blockers. J Biol Chem 2003; 278:50212-50216
74. De S, Miller DW, Robinson DH. Effect of particle size of nanospheres and microspheres on the cellular association and cytotoxicity of paclitaxel in 4T1 cells. Pharm Res 2005; 22:766-775
75. Olivier V, Duval JL, Hindie M, Pouletaut P, Nagel MD. Comparative particleinduced cytotoxicity toward macrophages and fibroblasts. Cell Biol Toxicol 2003; 19:145-159
76. Seki J, Sonoke S, Saheki A, Fukui H, Sasaki H, Mayumi T. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int J Pharm 2004; 273:75-83
77. Huang M, Khor E, Lim LY. Uptake and cytotoxicity of chitosan molecules and nanoparticles:Effects of molecular weight and degree of deacetylation. Pharm Res 2004; 21:344-353
78. Szenkuti L. Light microscopic observations on luminally administered dyes, dextranes, nanospheres and microspheres in the pre-epithelial mucus gel layer of the rat distal colon. J Control Release 1997; 46:233-242
79. Moghimi SM, Patel HM. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system, the concept of tissue specificity. Adv Drug Deliv Res 1998; 32:45-60
80. Senior J, Gregoriadis G. Is half-life of circulating small unilamellar liposomes determined by changes in their permeability? FEBS Lett 1982; 145: 109-114
81. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target specific nanoparticles: Theory and practice. Pharmacol Rev 2001; 53:283-318
82. Gessner A, Lieske A, Paulke B, Muller R. Influence of surface charge density on protein adsorption on polymeric nanoparticles: Analysis by twodimensional electrophoresis. Eur J Pharm Biopharm 2002; 54:165-170
83. Curtis J, Greenberg M, Kester J, Phillips S, Krieger G. Nanotechnology and nanotoxicology: A primer for clinicians. Toxicol Sci 2006; 25:245-260
84. Miller J. Beyond biotechnology: FDA regulation of nanomedicine. Columbia Sci Technol Rev 2003; 5:1-29
85. Chan VS. Nanomedicine: An unresolved regulatory issue. Regul Toxicol Pharmacol 2006; 46:218-224